Theravance Biopharma (TBPH) EPS (Diluted) Growth (1y) (2018 - 2026)
Theravance Biopharma (TBPH) EPS (Diluted) Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 8.02% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -4.52% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 96.09% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 144.25% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -99.90% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -11.18% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 315.14% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 96.41% |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | -110.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -110.56% |
| Mar 31, 2026 | 64.52% |
| Dec 31, 2025 | 274.98% |
| Sep 30, 2025 | 126.89% |
| Jun 30, 2025 | 418.81% |
| Mar 31, 2025 | -13.09% |
| Dec 31, 2024 | -231.49% |
| Sep 30, 2024 | -51.49% |
| Jun 30, 2024 | -22.85% |
| Mar 31, 2024 | 29.90% |
| Dec 31, 2023 | -281.22% |
| Sep 30, 2023 | -101.39% |
| Jun 30, 2023 | -214.54% |
| Mar 31, 2023 | -266.31% |
| Dec 31, 2022 | -85.74% |
| Sep 30, 2022 | 4,284.34% |
| Jun 30, 2022 | 27.09% |
| Mar 31, 2022 | 96.21% |
| Dec 31, 2021 | 130.75% |
| Sep 30, 2021 | 124.07% |